WO2007084661A3 - Therapy-enhancing glucan - Google Patents

Therapy-enhancing glucan Download PDF

Info

Publication number
WO2007084661A3
WO2007084661A3 PCT/US2007/001427 US2007001427W WO2007084661A3 WO 2007084661 A3 WO2007084661 A3 WO 2007084661A3 US 2007001427 W US2007001427 W US 2007001427W WO 2007084661 A3 WO2007084661 A3 WO 2007084661A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
glucan
therapy
antitumor
mammal
Prior art date
Application number
PCT/US2007/001427
Other languages
French (fr)
Other versions
WO2007084661B1 (en
WO2007084661A2 (en
Inventor
Rolf Einar Engstad
Original Assignee
Sloan Kettering Inst Cancer
Biotec Pharmacon Asa
Rolf Einar Engstad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/334,763 external-priority patent/US7906492B2/en
Application filed by Sloan Kettering Inst Cancer, Biotec Pharmacon Asa, Rolf Einar Engstad filed Critical Sloan Kettering Inst Cancer
Priority to JP2008551413A priority Critical patent/JP2009528267A/en
Priority to CA002637205A priority patent/CA2637205A1/en
Priority to PCT/US2007/001427 priority patent/WO2007084661A2/en
Priority to EP07718218A priority patent/EP1984004A4/en
Priority to US12/161,285 priority patent/US8323644B2/en
Publication of WO2007084661A2 publication Critical patent/WO2007084661A2/en
Publication of WO2007084661A3 publication Critical patent/WO2007084661A3/en
Publication of WO2007084661B1 publication Critical patent/WO2007084661B1/en
Priority to AU2008207369A priority patent/AU2008207369B2/en
Priority to US12/212,352 priority patent/US20090053221A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Abstract

A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a yeast beta-glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal. The above therapeutic composition may further comprise antitumor antibodies or cancer vaccine composition, wherein the antitumor activitiesof the antitumor antibodies or the cancer vaccine composition are enhanced by the yeast glucan.
PCT/US2007/001427 2006-01-17 2007-01-17 Therapy-enhancing glucan WO2007084661A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2008551413A JP2009528267A (en) 2006-01-17 2007-01-17 Glucan to enhance treatment
CA002637205A CA2637205A1 (en) 2006-01-17 2007-01-17 Therapy-enhancing glucan
PCT/US2007/001427 WO2007084661A2 (en) 2006-01-17 2007-01-17 Therapy-enhancing glucan
EP07718218A EP1984004A4 (en) 2006-01-17 2007-01-17 Therapy-enhancing glucan
US12/161,285 US8323644B2 (en) 2006-01-17 2007-01-17 Therapy-enhancing glucan
AU2008207369A AU2008207369B2 (en) 2006-01-17 2008-08-18 Immune response enhancing glucans
US12/212,352 US20090053221A1 (en) 2006-01-17 2008-09-17 Immune response enhancing glucan

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/334,763 US7906492B2 (en) 2001-01-16 2006-01-17 Therapy-enhancing glucan
US11/334,763 2006-01-17
PCT/US2007/001427 WO2007084661A2 (en) 2006-01-17 2007-01-17 Therapy-enhancing glucan

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/334,763 Continuation-In-Part US7906492B2 (en) 2001-01-16 2006-01-17 Therapy-enhancing glucan

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2008207369A Division AU2008207369B2 (en) 2006-01-17 2008-08-18 Immune response enhancing glucans
US12/212,352 Continuation-In-Part US20090053221A1 (en) 2006-01-17 2008-09-17 Immune response enhancing glucan

Publications (3)

Publication Number Publication Date
WO2007084661A2 WO2007084661A2 (en) 2007-07-26
WO2007084661A3 true WO2007084661A3 (en) 2007-11-08
WO2007084661B1 WO2007084661B1 (en) 2008-01-10

Family

ID=40382391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/001427 WO2007084661A2 (en) 2006-01-17 2007-01-17 Therapy-enhancing glucan

Country Status (4)

Country Link
EP (1) EP1984004A4 (en)
JP (1) JP2009528267A (en)
AU (1) AU2008207369B2 (en)
WO (1) WO2007084661A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
JP5153188B2 (en) * 2007-03-30 2013-02-27 小林製薬株式会社 Th1 / Th2 balance improver
EP2219655A2 (en) * 2007-11-13 2010-08-25 Biotec Pharmacon ASA Methods of treating or preventing inflammatory diseases of the intestinal tract
WO2012014978A1 (en) * 2010-07-29 2012-02-02 国立大学法人北海道大学 Immune adjuvant
WO2012105219A1 (en) * 2011-01-31 2012-08-09 オリンパス株式会社 Antibody therapy effect-enhancing drug
RU2018102251A (en) 2012-04-30 2019-02-21 Байотера, Инк. METHODS OF β-GLUCANE IMMUNOTHERAPY
EP2832360A1 (en) 2013-07-30 2015-02-04 Fresenius Kabi Deutschland GmbH Polysaccharide for use in preventing metastasis formation and/or relapse
CN106687122B (en) * 2014-07-10 2020-11-10 百奥赛诺公司 Combination of beta-glucan and an anti-cancer agent affecting the tumor microenvironment
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
MX2020009510A (en) * 2018-03-13 2021-08-05 Hibercell Inc Beta glucan and cd40 agonist combination immunotherapy.
US20210236630A1 (en) * 2018-04-24 2021-08-05 Memorial Sloan Kettering Cancer Center Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans
WO2020061203A1 (en) * 2018-09-21 2020-03-26 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
JP7048102B2 (en) 2019-05-23 2022-04-05 国立研究開発法人医薬基盤・健康・栄養研究所 Application of nucleic acid polysaccharide complex with immunostimulatory activity as an antitumor drug

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130127A (en) * 1985-03-11 1992-07-14 The Wistar Institute Human tumor therapy using beta (1-3) glucanlentinan and anti-tumor antibodies
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5849720A (en) * 1989-09-08 1998-12-15 Alpha-Beta Technology, Inc. Enhancement of non-specific immune defenses by administration of underivatized, aqueous soluble glucans
US20060009419A1 (en) * 2002-09-04 2006-01-12 Ross Gordon D Therapy-enhancing glucan

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
NO300692B1 (en) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilized branched β-1,3-glucan and its use, as well as the use of unsolubilized branched β-1,3-glucan
WO1997035619A1 (en) * 1996-03-28 1997-10-02 Genitrix, L.L.C. Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
JP2004507446A (en) * 2000-02-04 2004-03-11 トーマス・ジェファーソン・ユニバーシティ Immunotherapy of low-dose haptenized tumor cells and tumor cell extracts
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1357919B1 (en) * 2001-01-16 2017-04-05 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
WO2006119395A2 (en) * 2005-05-03 2006-11-09 Biopolymer Engineering, Inc. Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130127A (en) * 1985-03-11 1992-07-14 The Wistar Institute Human tumor therapy using beta (1-3) glucanlentinan and anti-tumor antibodies
US5849720A (en) * 1989-09-08 1998-12-15 Alpha-Beta Technology, Inc. Enhancement of non-specific immune defenses by administration of underivatized, aqueous soluble glucans
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US20060009419A1 (en) * 2002-09-04 2006-01-12 Ross Gordon D Therapy-enhancing glucan

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HELLSTOM ET AL.: "Antitumor effects of L6, an IgG2 antibody that reacts with most human carcinomas", PROC. NATL. ACAD. SCI. USA, vol. 83, September 1986 (1986-09-01), pages 7059 - 7063, XP000939048 *
HERRERA ET AL.: "Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro", LEUKEMIA, vol. 14, no. 5, 2000, pages 853 - 858, XP008060428 *
MENDELSOHN J.: "Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy", CLINICAL CANCER RESEARCH, vol. 3, 1997, pages 2703 - 2707, XP002938234 *
RAI ET AL.: "Monoclonal antibodies in chronic lymphocytic leukemia", REVIEWS IN CLINICAL AND EXPERIMENTAL HEMATOLOGY, vol. 4, no. 2, 2000, pages 134 - 144, XP008128870 *
YAN ET AL.: "B-Glucan, a "specific" biologic response modifier that uses antibodies to target tumor for cytotoxic recognition by Leukocyte complement receptor type 3 (CD11B/CD18)", THE JOURNAL OF IMMUNOLOGY, vol. 163, 1999, pages 3045 - 3052, XP008128976 *

Also Published As

Publication number Publication date
WO2007084661B1 (en) 2008-01-10
AU2008207369A1 (en) 2008-09-11
EP1984004A4 (en) 2010-03-03
EP1984004A2 (en) 2008-10-29
WO2007084661A2 (en) 2007-07-26
JP2009528267A (en) 2009-08-06
AU2008207369B2 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
WO2007084661A3 (en) Therapy-enhancing glucan
WO2007100902A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
WO2011157741A3 (en) Human antibody drug conjugates against tissue factor
EP2016173A4 (en) Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
EP2476704A3 (en) Humanized monoclonal antibodies to heptocyte growth factor
WO2010066803A3 (en) Human antibodies against human tissue factor
WO2006093784A3 (en) Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
WO2009052411A3 (en) Methods for treatment of thiol-containing compound deficient conditions
WO2009064460A3 (en) Gastrointestinal delivery systems
WO2008116195A3 (en) Compositions comprising an sglt2 ingibitor for treating obesity
WO2008036206A3 (en) Copolymer-bioceramic composite implantable medical devices
WO2008083174A3 (en) Compositions and methods for the treatment of infections and tumors
WO2009049184A9 (en) Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
WO2007107305A3 (en) Treatment of triple receptor negative breast cancer
WO2006066074A3 (en) Lung-targeted drugs
WO2007135546A3 (en) TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
WO2008014200A3 (en) Cyclosporin compositions
WO2006050155A3 (en) Cancer therapeutic compositions
EP2952210A3 (en) Compositions comprising saccharide binding moieties and methods for targeted therapy
WO2008066784A3 (en) Expression of foxp3 by cancer cells
WO2007098106A3 (en) Respiratory tract delivery of interferon-tau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2637205

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008551413

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12161285

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1729/MUMNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007718218

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200780007540.0

Country of ref document: CN